Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

BACKGROUND: Evolocumab significantly lowers low‐density lipoprotein cholesterol (LDL‐C) when dosed 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM) subcutaneously. HYPOTHESIS: LDL‐C changes are comparable among different patient subgroups in a pooled analysis of data from phase 3 trials. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroes, Erik, Robinson, Jennifer G., Raal, Frederick J., Dufour, Robert, Sullivan, David, Kassahun, Helina, Ma, Yuhui, Wasserman, Scott M., Koren, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2018
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489970/
https://www.ncbi.nlm.nih.gov/pubmed/30120772
http://dx.doi.org/10.1002/clc.23049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489970/
https://www.ncbi.nlm.nih.gov/pubmed/30120772
http://dx.doi.org/10.1002/clc.23049

Ejemplares similares